Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28304390 | 1.00 | TSHR (0.35) | TSHRNAPRTTDP1CYP11B2 | |
| Pyridine SCHEMBL18210482 | 0.98 | TSHR (0.36) | TSHRNAPRTTDP1CYP11B2 | |
| Pyridine SCHEMBL30530223 | 0.93 | TSHR (0.30) | TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL29359954 | 0.93 | TSHR (0.30) | TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL27607142 | 0.81 | TSHR (0.35) | TSHRNAPRTTDP1CYP11B2 | |
| SCHEMBL10803233 | 0.79 | — | — | |
| Pyridine SCHEMBL10582176 | 0.78 | TSHR (0.36) | TSHRNAPRTTDP1CYP11B2 | |
| Benzene SCHEMBL9464137 | 0.76 | KDM4E (0.30) | — | |
| Pyridine SCHEMBL4533918 | 0.76 | TSHR (0.60) | TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL9510891 | 0.73 | TSHR (0.64) | TSHRNAPRTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443129-B1 | PROCESS FOR HYDROGENATION OF HALOGENOALKENES WITHOUT DEHALOGENATION | LEK PHARMACEUTICALS (SI) | 2016-11-23 | — | — | EP | claimed |
| EP-0306210-B1 | A NOVEL HYDROGENATION PROCESS FOR THE FORMATION OF DI OR TETRAHYDRO HMG-COA REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1993-09-29 | — | — | EP | claimed |
| US-10975091-B2 | Pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2021-04-13 | — | — | US | disclosed |
| EP-3269721-B1 | BICYCLIC PYRIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2021-04-07 | — | — | EP | disclosed |
| EP-3150581-B1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2020-04-15 | — | — | EP | disclosed |
| US-20200055868-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-10421762-B2 | Pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20180327418-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2018-11-15 | — | — | US | disclosed |
| US-10059720-B2 | Pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2018-08-28 | — | — | US | disclosed |
| US-10023583-B2 | Bicyclic pyridine compound | ASTELLAS PHARMA INC. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20180022755-A1 | BICYCLIC PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2018-01-25 | — | — | US | disclosed |
| EP-3269721-A1 | BICYCLIC PYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20170190715-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2017-07-06 | — | — | US | disclosed |
| EP-2072537-B1 | Hydrogenation of diene-based polymers | LANXESS INC (CA) | 2014-01-29 | — | — | EP | disclosed |
| EP-2072536-A1 | Hydrogenation of diene-based polymers | Lanxess Inc. (CA) | 2009-06-24 | — | — | EP | disclosed |
| EP-2072537-A1 | Hydrogenation of diene-based polymers | Lanxess Inc. (CA) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055868-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | TSHR 4655/4885NAPRT 687/4885TDP1 3910/4885 |
| US-10975091-B2 | Pyridine derivative | LAP3, PREP, DNPEP | TSHR 4655/4885NAPRT 687/4885TDP1 3910/4885 |
| US-20180327418-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | TSHR 4655/4885NAPRT 687/4885TDP1 3910/4885 |
| US-10023583-B2 | Bicyclic pyridine compound | LAP3, PREP, DNPEP | TSHR 4578/4885NAPRT 555/4885TDP1 3988/4885 |
| US-10059720-B2 | Pyridine derivative | LAP3, PREP, DNPEP | TSHR 4655/4885NAPRT 687/4885TDP1 3910/4885 |
| US-10421762-B2 | Pyridine derivative | LAP3, PREP, DNPEP | TSHR 4655/4885NAPRT 687/4885TDP1 3910/4885 |
| US-20170190715-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | TSHR 4655/4885NAPRT 687/4885TDP1 3910/4885 |
| US-20180022755-A1 | BICYCLIC PYRIDINE COMPOUND | LAP3, PREP, DNPEP | TSHR 4578/4885NAPRT 555/4885TDP1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.